Biontech acquires mabvax therapeutics’ antibody assets ledderhose disease diet to expand portfolio – biontech

Mainz, Germany, May 8, 2019 – BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious ledderhose disease diet diseases, announced today the acquisition of antibody assets and infrastructure from ledderhose disease diet San Diego-based MabVax Therapeutics Holding, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company.

Under the terms of the agreement, BioNTech has acquired MabVax Therapeutics’ lead candidate, MVT-5873, as well as other pre-clinical antibody assets to expand and complement its existing antibody ledderhose disease diet portfolio and proprietary RiboMABS development capabilities. The acquired lead asset is currently in Phase 1 clinical ledderhose disease diet development in pancreatic cancer and has been tested in 35 ledderhose disease diet patients with initial positive interim data announced in February 2018. MVT-5873 is a fully human IgG1 monoclonal antibody targeting sialyl ledderhose disease diet Lewis A (sLea), an epitope expressed in pancreatic and other GI cancers that ledderhose disease diet plays a role in tumor adhesion and metastasis formation.

“BioNTech’s vision is to identify and provide the best therapeutic ledderhose disease diet options for each individual cancer patient. To make this possible, we are developing and integrating complementary technologies and drug modalities ledderhose disease diet into our overall portfolio of treatment approaches,” said Prof. Dr. Ugur Sahin, CEO of BioNTech. “MabVax Therapeutics has developed an antibody with a novel mode ledderhose disease diet of action in a disease indication that complements our pipeline ledderhose disease diet expansion plans. This clinical-stage antibody together with the other pre-clinical assets that we have acquired from MabVax Therapeutics enhance ledderhose disease diet our antibody portfolio, which also benefits from our ongoing collaboration with Genmab and ledderhose disease diet the acquisition of MAB Discovery earlier this year.”

In conjunction with the agreement, BioNTech has purchased MabVax Therapeutics’ infrastructure and laboratory equipment with the intention of establishing a ledderhose disease diet research facility in San Diego. The location is advantageous for BioNTech’s planned US-based clinical trials and will further support production of the ledderhose disease diet Company’s investigational treatments. Financial terms were not disclosed.

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for ledderhose disease diet individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and ledderhose disease diet individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate ledderhose disease diet partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its ledderhose disease diet majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. For more information, please see: